Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
31,723,980
-
Share change
-
+1,012,365
-
Total reported value
-
$638,582,573
-
Put/Call ratio
-
54%
-
Price per share
-
$20.13
-
Number of holders
-
95
-
Value change
-
+$17,643,380
-
Number of buys
-
41
-
Number of sells
-
47
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2018
As of 31 Dec 2018,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,723,980 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, JPMORGAN CHASE & CO, BlackRock Inc., FRANKLIN RESOURCES INC, Bank of New York Mellon Corp, ArrowMark Colorado Holdings LLC, Vanguard Group Inc, ALLIANCEBERNSTEIN L.P., NovaQuest Capital Management, L.L.C., and Capital World Investors.
This page lists
96
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.